US20170342383A1 - Lithium disilicate glass-ceramic compositions and methods thereof - Google Patents
Lithium disilicate glass-ceramic compositions and methods thereof Download PDFInfo
- Publication number
- US20170342383A1 US20170342383A1 US15/603,006 US201715603006A US2017342383A1 US 20170342383 A1 US20170342383 A1 US 20170342383A1 US 201715603006 A US201715603006 A US 201715603006A US 2017342383 A1 US2017342383 A1 US 2017342383A1
- Authority
- US
- United States
- Prior art keywords
- glass
- composition
- ceramic
- crystalline phase
- bioactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C10/00—Devitrified glass ceramics, i.e. glass ceramics having a crystalline phase dispersed in a glassy phase and constituting at least 50% by weight of the total composition
- C03C10/0018—Devitrified glass ceramics, i.e. glass ceramics having a crystalline phase dispersed in a glassy phase and constituting at least 50% by weight of the total composition containing SiO2, Al2O3 and monovalent metal oxide as main constituents
- C03C10/0027—Devitrified glass ceramics, i.e. glass ceramics having a crystalline phase dispersed in a glassy phase and constituting at least 50% by weight of the total composition containing SiO2, Al2O3 and monovalent metal oxide as main constituents containing SiO2, Al2O3, Li2O as main constituents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C10/00—Devitrified glass ceramics, i.e. glass ceramics having a crystalline phase dispersed in a glassy phase and constituting at least 50% by weight of the total composition
- C03C10/0009—Devitrified glass ceramics, i.e. glass ceramics having a crystalline phase dispersed in a glassy phase and constituting at least 50% by weight of the total composition containing silica as main constituent
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C21/00—Treatment of glass, not in the form of fibres or filaments, by diffusing ions or metals in the surface
- C03C21/001—Treatment of glass, not in the form of fibres or filaments, by diffusing ions or metals in the surface in liquid phase, e.g. molten salts, solutions
- C03C21/002—Treatment of glass, not in the form of fibres or filaments, by diffusing ions or metals in the surface in liquid phase, e.g. molten salts, solutions to perform ion-exchange between alkali ions
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/04—Glass compositions containing silica
- C03C3/076—Glass compositions containing silica with 40% to 90% silica, by weight
- C03C3/083—Glass compositions containing silica with 40% to 90% silica, by weight containing aluminium oxide or an iron compound
- C03C3/085—Glass compositions containing silica with 40% to 90% silica, by weight containing aluminium oxide or an iron compound containing an oxide of a divalent metal
- C03C3/087—Glass compositions containing silica with 40% to 90% silica, by weight containing aluminium oxide or an iron compound containing an oxide of a divalent metal containing calcium oxide, e.g. common sheet or container glass
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/04—Glass compositions containing silica
- C03C3/076—Glass compositions containing silica with 40% to 90% silica, by weight
- C03C3/097—Glass compositions containing silica with 40% to 90% silica, by weight containing phosphorus, niobium or tantalum
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/04—Glass compositions containing silica
- C03C3/076—Glass compositions containing silica with 40% to 90% silica, by weight
- C03C3/11—Glass compositions containing silica with 40% to 90% silica, by weight containing halogen or nitrogen
- C03C3/111—Glass compositions containing silica with 40% to 90% silica, by weight containing halogen or nitrogen containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/04—Glass compositions containing silica
- C03C3/076—Glass compositions containing silica with 40% to 90% silica, by weight
- C03C3/11—Glass compositions containing silica with 40% to 90% silica, by weight containing halogen or nitrogen
- C03C3/112—Glass compositions containing silica with 40% to 90% silica, by weight containing halogen or nitrogen containing fluorine
- C03C3/115—Glass compositions containing silica with 40% to 90% silica, by weight containing halogen or nitrogen containing fluorine containing boron
- C03C3/118—Glass compositions containing silica with 40% to 90% silica, by weight containing halogen or nitrogen containing fluorine containing boron containing aluminium
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C4/00—Compositions for glass with special properties
- C03C4/0007—Compositions for glass with special properties for biologically-compatible glass
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C4/00—Compositions for glass with special properties
- C03C4/0007—Compositions for glass with special properties for biologically-compatible glass
- C03C4/0014—Biodegradable glass
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C2204/00—Glasses, glazes or enamels with special properties
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C2205/00—Compositions applicable for the manufacture of vitreous enamels or glazes
- C03C2205/06—Compositions applicable for the manufacture of vitreous enamels or glazes for dental use
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C2214/00—Nature of the non-vitreous component
- C03C2214/20—Glass-ceramics matrix
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/10—Mineral substrates
- C12N2533/12—Glass
Definitions
- the disclosure relates to glass-ceramic compositions, bioactive glass-ceramic compositions and articles made from the glass-ceramic compositions, and to methods of making and using the bioactive glass-ceramic compositions and articles.
- the disclosure provides a group of glass-ceramic compositions each having lithium disilicate as a first major crystal phase, and at least one of wollastonite, fluoroapatite, cristobalite, ⁇ -quartz, lithiophosphate, or a mixture thereof, as a second minor phase.
- the disclosed compositions can comprise a source of, for example, 50 to 75 wt % SiO 2 , 1 to 5 wt % Al 2 O 3 , 1 to 8 wt % P 2 O 5 , 2 to 10 wt % CaO, 5 to 20 wt % Li 2 O, 0.5 to 5 wt % Na 2 O, 0.5 to 8 wt % ZrO 2 , and 0.1 to 1.0 F ⁇ wt % (i.e., fluoride ion), based on a 100 wt % total of the composition.
- a source of for example, 50 to 75 wt % SiO 2 , 1 to 5 wt % Al 2 O 3 , 1 to 8 wt % P 2 O 5 , 2 to 10 wt % CaO, 5 to 20 wt % Li 2 O, 0.5 to 5 wt % Na 2 O, 0.5 to 8 wt % ZrO 2 , and 0.1 to
- the disclosed compositions can further comprise a source of, for example, 0.1 to 10 wt % B 2 O 3 , based on a 100 wt % total of the composition.
- the disclosure provides a glass-ceramic composition or glass-ceramic articles made from the composition, having a combination of high strength and high toughness.
- the disclosure provides a glass-ceramic composition having excellent biocompatibility.
- the disclosure provides methods of making and using the disclosed compositions.
- FIG. 1 shows X-ray diffraction spectra of example compositions 7 to 10. All specimens were cerammed using a cycle of 700° C. for 2 hr and then 800° C. for 4 hr.
- FIGS. 2A to 2D show SEM images of polished surfaces in example compositions 7 to 10 corresponding to FIGS. 2A, 2B, 2C, and 2D , respectively.
- FIGS. 3A to 3D show confocal SEM images of MC3T3 cell growth in disclosed compositions 7 to 10 corresponding to FIGS. 3A, 3B, 3C, and 3D , respectively.
- FIGS. 4A and 4B show Day 1 attachment and proliferation of MC3T3 cells on disclosed bioactive glass-ceramic discs: absolute level (absolute cell number; 4 A) and relative levels with respect to an in vitro control: a Tissue Culture Treated® (TCT) well (relative cell number; 4 B).
- absolute level absolute cell number
- TCT Tissue Culture Treated®
- FIGS. 5A and 5B show cell proliferation results for disclosed compositions 7 to 10.
- the disclosed method of making and using provide one or more advantageous features or aspects, including for example as discussed below.
- Features or aspects recited in any of the claims are generally applicable to all facets of the invention. Any recited single or multiple feature or aspect in any one claim can be combined or permuted with any other recited feature or aspect in any other claim or claims.
- Glass Glass, “glasses,” or like terms can refer to a glass or a glass-ceramic.
- Glass article can refer to any object made wholly or partly of any of the disclosed glass or glass-ceramic compositions.
- Bioactivity Index index of bioactivity
- I B index of bioactivity
- osteoproductive Class A having both intracellular and extracellular responses, e.g., 45S5 Bioglass®
- osteoconductive Class B extracellular response only at interface, e.g., synthetic hydroxyapatite
- the term “about” also encompasses amounts that differ due to aging of a composition or formulation with a particular initial concentration or mixture, and amounts that differ due to mixing or processing a composition or formulation with a particular initial concentration or mixture.
- indefinite article “a” or “an” and its corresponding definite article “the” as used herein means at least one, or one or more, unless specified otherwise.
- compositions and methods of the disclosure can include any value or any combination of the values, specific values, more specific values, and preferred values described herein, including explicit or implicit intermediate values and ranges.
- Bioactive materials having high strength and toughness are in significant demand, for example, for the regeneration of bone and teeth.
- Glass-ceramics based on lithium disilicate offer highly desirable mechanical properties, including high body strength and fracture toughness, due to their microstructures of randomly-oriented interlocking crystals.
- Glass-ceramics having fracture toughness values of 2 to 3 MPa ⁇ m 1/2 are achievable in the system of glass-ceramics based on lithium disilicate compositions (see commonly owned and assigned U.S. Ser. No. 61/874,870).
- Lithium disilicate glass-ceramics have been widely used in the fabrication of single and multiple dental restorations. However, these glass-ceramics have not been used in bone repair due to their relatively low bioactivity.
- bioceramics based on apatite and wollastonite have demonstrated high bioactivity but do not have sufficient mechanical strength compared to, for example, cortical bone (Hench, L. L., Bioceramics, J Am Ceram Soc, 1998, 81: 1705-1728).
- the disclosure provides a group of glass-ceramic compositions having a phase assemblage containing a major phase of lithium disilicate and a minor phase or phases of, for example, apatite or wollastonite.
- These superior compositions exhibit an excellent combination of high mechanical strength and high bioactivity, which makes them excellent for hard tissue regeneration.
- WO 2015200017 ('017), entitled “Process for producing a sintered lithium disilicate glass ceramic dental restoration and kit of parts,” mentions a process for producing a sintered lithium disilicate glass ceramic dental restoration out of a porous 3-dim article.
- the presently disclosed compositions have a different phase assemblage, for example, the disclosed compositions have lithium disilicate and apatite, whereas '017 has only lithium disilicate, and the presently disclosed compositions are bioactive but not the '017 compositions. Additionally, the presently disclosed compositions have CaO and F ⁇ to produce the apatite phase.
- U.S. Pat. No. 7,166,548 mentions an apatite glass ceramic, which contains at least one glass phase and at least one apatite phase and is characterized in that at least one of the apatite phases is a phosphate-free and fluorine-free siliceous oxyapatite phase.
- these materials exclude phosphate and fluorine, which is present in the presently disclosed compositions.
- the disclosure provides a glass-ceramic composition, comprising:
- the disclosure provides a glass-ceramic composition wherein the first crystalline phase and the second crystalline phase, in combination, comprise a source of:
- the glass-ceramic composition can further comprise a source of 0.1 to 10 wt % B 2 O 3 , based on a 100 wt % total of the composition.
- the first crystalline phase and the second crystalline phase in combination, can comprise a source of:
- the abovementioned composition can be a preferred or a most preferred composition and can comprise, consist of, or consist essentially of, the abovementioned composition components.
- the disclosed bioactive compositions and articles can be a preferred or most preferred composition or article and can comprise, consist of, or consist essentially of, the disclosed bioactive composition or article.
- the disclosed methods of making and methods of using can be a preferred or most preferred method and can comprise, consist of, or consist essentially of, the disclosed methods.
- the composition can have a high strength of from 200 MPa to 500 MPa, for example, from at least 200 MPa, at least 300 MPa, or at least 400 MPa, including intermediate values and ranges.
- the composition can have a high fracture toughness of from 1.4 to 2.0 MPa ⁇ m 1/2 , for example, from at least 1.4, 1.6, 1.8, or 2.0 MPa ⁇ m 1/2 , including intermediate values and ranges.
- the composition can have a combination of high strength of from 200 MPa to 500 MPa, and high fracture toughness of from 1.4 to 2.0 MPa ⁇ m 1/2 .
- the composition can be prepared from a precursor glass composition comprising a source of, for example:
- the abovementioned precursor glass composition does not change significantly upon ceramming.
- the disclosure provides a method of making the abovementioned glass-ceramic compositions comprising, for example:
- the method of making can further comprise, for example, ion exchanging the resulting glass-ceramic composition to create at least one compressive stress layer on at least one surface of the article to increase mechanical strength of the article.
- the disclosure provides a bioactive composition, comprising:
- the glass-ceramic composition can comprise, for example, a source of:
- the glass-ceramic composition can comprise, for example, a source of:
- the abovementioned bioactive composition can further comprise, for example, a source of 0.1 to 10 wt % B 2 O 3 , based on a 100 wt % total of the composition.
- the disclosure provides a method of culturing osteoblast cells, i.e., a method of using the disclosed bioactive composition, comprising, for example:
- the glass-ceramic composition of the bioactive composition can be combined or contacted with the suitable liquid medium prior to being contacted with the live osteoblast cell(s).
- the contacting produces a proliferation of the osteoblast cells on the surface of the bioactive composition.
- the contacting produces a proliferation of the osteoblast cells in the suitable liquid medium, such as the culture medium of MC3T3 cells: i.e., alpha-MEM supplemented with 10% fetal bovine serum and 1 mM sodium pyruvate.
- suitable liquid medium such as the culture medium of MC3T3 cells: i.e., alpha-MEM supplemented with 10% fetal bovine serum and 1 mM sodium pyruvate.
- the suitable liquid medium can include, for example, a simulated body fluid (SBF) composition.
- SBF is used for testing apatite formation activity of bioactive glasses/glass-ceramics.
- the disclosed bioactive glass-ceramics form in-situ a biologically active apatite layer (e.g., the mineral phase of bone and teeth) that can bond to bone and teeth, and can even bond to soft tissue.
- a biologically active apatite layer e.g., the mineral phase of bone and teeth
- the potential applications of the disclosedbioactive glass-ceramics can include, for example, monolithic articles, composites, films, coating, or like forms, for use in repair of load-bearing bones, dental regeneration, treatment of dental hypersensitivity, artificial vertebrae, spinous spacers, intervertebral spacers, iliac spacers, granular fillers, scaffolds, middle-ear implant and in other types of small-bone replacement, wound healing, and like applications.
- the disclosed bioactive glass-ceramics are biocompatible with, for example, osteoblasts, keratinocytes, human umbilical vein endothelial cells (HUVEC), etc. (see for example, T. Kokubo et al., “How useful is SBF in predicting in vivo bone bioactivity?”, Biomaterials, 27[15] 2907-15 (2006)).
- the disclosed compositions and disclosed bioactive compositions can also have application in, for example: angiogenesis (HUVEC cells), wound healing (keratinocytes), bone tissue engineering (MC3T3 cells), and like applications.
- angiogenesis HUVEC cells
- wound healing keratinocytes
- M3T3 cells bone tissue engineering
- the disclosed composition is biocompatible with various cell types in various applications, and are biologically active (i.e., bioactive).
- compositions and methods thereof are advantaged in several aspects, including for example:
- the disclosed bioactive glass-ceramic compositions can further comprise, for example, a form factor selected from a hollow microsphere, a solid microsphere, or a combination thereof, that is, where the glass composition has a particle shape, such as a sphere, an elongated sphere or egg-shape, a rod, or like geometries.
- Table 1 lists representative examples of the disclosed compositions. The ceramming cycle for all examples 1 to 15 was 700° C. for 2 hr and 800° C. for 4 hr.
- Phase assemblage key Lithium disilicate, cristobalite, wollastonite, ⁇ -quartz, lithiophosphate.
- B Lithium disilicate, wollastonite, lithiophosphate.
- C Lithium disilicate, lithium metasilicate, wollastonite, lithiophosphate.
- D Lithium disilicate, ⁇ -quartz, lithiophosphate.
- E Lithium disilicate, cristobalite, fluoroapatite, ⁇ -quartz.
- F Lithium disilicate, fluoroapatite, ⁇ -quartz, lithiophosphate.
- G Lithium disilicate, fluoroapatite, lithium metasilicate, ⁇ -quartz.
- H Lithium disilicate, fluoroapatite, ⁇ -quartz.
- the disclosed compositions can be free of (e.g., zero ppm or ppb), or substantially free of (e.g., trace amounts less than several ppm or ppb), at least one of, for example, K 2 O, K 2 CO 3 , Ca 3 (PO 4 ) 2 , MgO, TiO 2 , As 2 O 3 , Sb 2 O 3 , or combinations or mixtures thereof.
- the disclosure provides precursor glass compositions that can be cerammed to produce glass-ceramics having excellent mechanical properties and biocompatibility.
- the disclosure provides glass-ceramics having high mechanical strength by forming an interlocking structure in the cerammed articles, which forces cracks to propagate along a tortuous path. Additionally, the presence of minor crystallite phases such as fluoroapatite and wollastonite in the disclosed compositions is beneficial to the growth, proliferation, and function of osteoblastic cell lines.
- the precursor glass or source glass can comprise, for example, 50 to 75 wt % SiO 2 , 1 to 5 wt % Al 2 O 3 , 5 to 20 wt % Li 2 O, 0.5 to 5 wt % Na 2 O, 0.5 to 8 wt % ZrO 2 , and 0.1 to 1.0 F ⁇ wt % (i.e., fluoride ion), based on a 100 wt % total of the composition.
- F ⁇ wt % i.e., fluoride ion
- a more preferred precursor glass composition can be, for example, 50 to 60 wt % SiO 2 , 1.0 to 3.0 wt % Al 2 O 3 , 0.1 to 4.0 wt % B 2 O 3 , 7.5 to 12.5 wt % Li 2 O, 0.5 to 2.0 wt % Na 2 O, 1.0 to 4.0 wt % ZrO 2 , and 0.2 to 0.8 wt % F ion based on a 100 weight percentage total (see Table 1).
- the precursor glasses can be cerammed into glass-ceramic articles having high crystallinity of, for example, 80% or more, such as 80 to 95%.
- the major crystallite phases are comprised of lithium disilicate.
- the minor crystallite phases can be comprised of, for example, fluoroapatite, wollastonite, cristobalite, ⁇ -quartz, lithiophosphate, or mixtures thereof depending on composition targeted.
- FIG. 1 shows X-ray diffraction spectra of example compositions 7 to 10, where the reference numerals 7, 8, 9, and 10, correspond to example compositions 7 to 10, respectively, in Table 1.
- the significant peaks are identified (with marker shapes) as: lithium disilicate (asterisk), lithium metasilicate (triangle), fluoroapatite (dot), beta-quartz (square), and cristobalite (diamond). All specimens were cerammed using a cycle of 700° C. for 2 hr and then 800° C. for 4 hr.
- the disclosed glass-ceramic articles composed of interlocking lithium disilicate can be easily obtained by ceramming precursor glasses at temperatures of from 700 to 900° C. for a period of time.
- a grain size of the lithium disilicate phase can be larger than 1 micrometer having a high aspect ratio that is typically formed in glass-ceramics.
- FIGS. 2A to 2D show SEM images of polished surfaces in example compositions 7 to 10 corresponding to FIGS. 2A, 2B, 2C, and 2D , respectively. All specimens were cerammed using a cycle of 700° C. for 2 hr and then 800° C. for 4 hr. Specimens were etched in 1% HF for one min prior to observation.
- interlocking crystals can be a significant factor in developing toughening mechanisms including, for example, crack deflection and tortuous crack path, which mechanisms can contribute to the observed high fracture toughness and high flexural strength (Table 1).
- a fracture toughness of over 1.5 MPa ⁇ m 1/2 and a flexural strength of over 300 MPa can be achieved in selected glass-ceramic compositions.
- the disclosed glass-ceramic product or residual glass can be ion exchanged to create a compressive stress layer in the surface of a ware to further improve mechanical strength.
- FIGS. 3A to 3D show confocal SEM images of MC3T3 cell growth in the disclosed compositions 7 to 10 corresponding to FIGS. 3A, 3B, 3C, and 3D , respectively. All specimens were cerammed using a cycle of 700° C. for 2 hr and then 800° C. for 4 hr. Cells were cultured one day, fixed with 4% formaldehyde, and then stained with Alexa Fluor 568 phalloidin and DAPI prior to the confocal imaging.
- the disclosed glass-ceramics can be manufactured using a thin rolling, a float, a casting process, and like methods; and scaffolds can be produced using, for example, rapid prototyping, polymer foam replication, particle sintering, and like methods. Glass-ceramics of desired forms can be used to support cell growth and hard tissue regeneration.
- the realized mechanical strength, biocompatibility, and biodegradation of the disclosed compositions can be influenced by the glass compositions.
- the disclosed glass compositions can further include, for example: SiO 2 which serves as the primary glass-forming oxide for precursor glass and can function to stabilize the networking structure of glass and glass-ceramics.
- the concentration of SiO 2 should be sufficiently high to form a lithium disilicate crystal phase when the precursor glass is heat treated to convert to a glass-ceramic (i.e., cerammed).
- the glasses can't contain too much SiO 2 since the melting temperature (200 poise temperature) of pure SiO 2 or high-SiO 2 glasses is undesirably high.
- glass or glass-ceramic compositions can comprise, for example, 68 to 82 wt % SiO 2 , based on a 100 wt % total weight.
- the Al 2 O 3 may also provide stabilization to the networking structure.
- Al 2 O 3 is favorable to the improvement of mechanical properties and chemical durability. However, too much Al 2 O 3 generally increases the viscosity of the melt and decreases the fraction of lithium disilicate crystals to an extent that no interlocking structure can be formed.
- the Al 2 O 3 concentration is preferably maintained in a reasonable range of, for example, from 1 to 5 wt %.
- the addition of B 2 O 3 can be beneficial to improved crack-resistance of the glass-ceramics, which is helpful for dental applications.
- a higher boron concentration can increase the degradation rate of the bioactive compositions, which property may be desired in applications such as bone regeneration.
- Li 2 O is another significant component in the disclosed precursor glass compositions.
- Li 2 O is advantageous for forming lithium disilicate crystal phases.
- Li 2 O is called for to have at least 8 wt % Li 2 O to obtain glass-ceramics having lithium disilicate as a predominant phase.
- the Li 2 O content gets too high, such as greater than 15 wt %, the precursor glasses become very fluid with low resistivity making it difficult to melt or form.
- the disclosed glass and glass-ceramic compositions can include, for example, from 2 to 6 wt % P 2 O 5 , for example, as a nucleating agent to produce bulk nucleation. If the P 2 O 5 concentration is too low, such as less than 2 wt %, the precursor glass does not crystallize. If the P 2 O 5 concentration is too high, such as greater than 6 wt %, the devitrification upon cooling during precursor glass forming, can be difficult to control.
- divalent cation oxides such as alkaline earth oxides
- divalent cation oxides can also be used to improve the melting behavior and the bioactivity of the glass.
- CaO was found to combine with P 2 O 5 to form apatite, or with SiO 2 to form wollastonite. Both apatite and wollastonite are known bioactive ceramics (see Hench, L. L., supra.).
- including Na 2 O in the precursor glass in an amount of from 0.1 to 5 wt % can reduce the melting temperature of the precursor glass, and can shorten the ceramming cycle. Furthermore, including Na 2 O in the precursor glass can also increase the thermal expansion after ceramming if a higher thermal expansion (i.e., CTE) is desired in the glass-ceramic articles.
- CTE thermal expansion
- melting was accomplished at an elevated temperature, such as above 1300° C., to fuse the precursor glass materials.
- ceramming was the heat treatment of the melted glass that was used to crystallize the glass into a glass-ceramic material.
- the precursor glass source materials Prior to melting, the precursor glass source materials were vigorously mixed in a plastic jar using a Turbula® mixer. Then the mixtures were transferred to a platinum crucible with an internal volume of approximately 650 cc and heated at 700° C. for 2 hr then 800° C. for 4 hr, and then the glass melt was poured on a steel plate, and annealed at 500° C.
- Glass-ceramic discs were prepared from cerammed parts. Precursor glass patties were cerammed in an electronic furnace using a cycle of 700° C. to 2 hr for nucleation and then 800° C. for 4 hr for crystal growth. After ceramming, the discs (12.5 mm in diameter ⁇ 2.0 mm thick) were core-drilled using a diamond drill, and then ground and polished to a 1.0 micrometer finish using a CeO 2 slurry. All finished discs were cleaned by sonicating in an ultrasonic sonicator for 10 min.
- Example 2 Glass-ceramic discs of Example 2 (made from compositions of the above working Example 1) were placed in wells of 24 well tissue culture treated microplates. Each composition has duplicate discs. MC 3T3 cells were then seeded (20K/2 mL) into the wells and some wells without any discs (Tissue Culture Treated (TCT) control). The microplates were cultured for 1, 4, or 7 days. Cells in the 1 day culture microplate were fixed with 4% formaldehyde, and then stained with Alexa Fluor 568 phalloidin and DAPI prior to the confocal imaging.
- FIGS. 4A and 4B show Day 1 attachment and proliferation of MC3T3 cells on disclosed bioactive glass-ceramic discs of Example compositions 7, 8, 9, and 19 (see Table 1) with respect to a reference bioactive glass control compositions 1 (C-1) and an in vitro control: a Tissue Culture Treated® (TCT) well: absolute level (absolute cell number; 4 A) and relative levels (relative cell number; 4 B).
- TCT Tissue Culture Treated®
- FIGS. 5A and 5B show cell proliferation results for disclosed compositions 7 to 10.
- Cells in the day 4 (D4) and day 7 (D7) culture plates were digested with the digestion buffer (125 microg/mL papain, 2 mM L-cysteine, 2 mM EDTA) at 65° C. for 16 hrs, the dsDNA amount was measured using Quant-iTTM PicoGreen® dsDNA Kit (Thermo Fisher). The increase of DNA concentration with increasing culture time provides additional evidence of their excellent biocompatibility.
- the digestion buffer 125 microg/mL papain, 2 mM L-cysteine, 2 mM EDTA
- MC3T3 cells were digested with papain and the amount of DNA was measured using a PicoGreen assay.
- D4 or D7 refers to Day 4 or Day 7 (as in “the 4 th day or 7 th day of cell culture”).
- TCT refers to a tissue culture treated microplate substrate available from Corning, Inc®. Glass-ceramic discs were placed in wells of 24 well tissue culture treated microplates. Each composition has duplicate discs.
- MC 3T3 cells were then seeded (20K/2 mL) into the wells and some wells without any discs (TCT control). The microplates were cultured for 4 or 7 days.
- cells were digested with a digestion buffer (D-PBS containing 125 microg/mL papain, 2 mM L-cysteine, 2 mMM EDTA) at 65° C. in humid environment with shaking (60 rpm) for 16 hrs.
- a digestion buffer D-PBS containing 125 microg/mL papain, 2 mM L-cysteine, 2 mMM EDTA
- the collected digestion solution was briefly centrifuged to remove any remaining particles.
- the dsDNA amount in the supernatant was measured using Quant-iTTM PicoGreen® dsDNA Kit (Thermo Fisher) according to the manufacturer's instruction.
- MC3T3E1 Subclone 14 (ATCC® CRL2594TM)(see atcc.org/products/all/CRL-2594.aspx).
- Quant-iTTM PicoGreen® dsDNA Kit (Invitrogen, #P11496). This kit contains Quant-iTTM PicoGreen® dsDNA Reagent (10 vials, each containing 100 microL aliquots), 25 mL of 20 ⁇ TE buffer, 1 mL of 100 microg/mL Lambda DNA (dsDNA standard), Papain (Sigma-Aldrich, #P4762-25MG), L-cysteine (Sigma-Aldrich, #C1276-10G), EDTA (Sigma-Aldrich, #E6511), D-PBS (Thermo Fisher, #14190), a shaker set to 65° C., and a plate reader.
- Quant-iTTM PicoGreen® dsDNA Reagent 10 vials, each containing 100 microL aliquots), 25 mL of 20 ⁇ TE buffer, 1 mL of 100 microg/mL Lambda DNA (dsDNA standard), Papain (Sigma-Ald
Abstract
A bioactive glass-ceramic composition as defined herein. Also disclosed are methods of making and using the disclosed compositions.
Description
- This application claims the benefit of priority under 35 U.S.C. §119 of U.S. Provisional Application Ser. No. 62/342,381 filed on May 27, 2016 the content of which is relied upon and incorporated herein by reference in its entirety.
- The present application is related commonly owned and assigned USSN Provisional Application Nos., filed concurrently herewith:
- 62/342,384, entitled “BIOACTIVE ALUMINOBORATE GLASSES”;
- 62/342,377, entitled “MAGNETIZABLE GLASS CERAMIC COMPOSITION AND METHODS THEREOF”;
- 62/342,391, entitled “BIODEGRADABLE MICROBEADS”;
- 62/342,411, entitled “BIOACTIVE GLASS MICROSPHERES”; and
- 62/342,426, entitled “BIOACTIVE BOROPHOSPHATE GLASSES”; but does not claim priority thereto.
- The present application is also related to commonly owned and assigned USSN Application Nos., 62/189,880, filed Jul. 7, 2015, entitled “ANTIMICROBIAL PHASE-SEPARATING GLASS AND GLASS CERAMIC ARTICLES AND LAMINATES,” which mentions a copper containing laminate having a degradable phase, which phase liberates cooper ion, and a non-degradable phase; and 61/874,870, filed Sep. 6, 2013, entitled “High strength glass-ceramics having lithium disilicate and beta-spodumene structures,” but does not claim priority thereto
- The entire disclosure of each publication or patent document mentioned herein is incorporated by reference.
- The disclosure relates to glass-ceramic compositions, bioactive glass-ceramic compositions and articles made from the glass-ceramic compositions, and to methods of making and using the bioactive glass-ceramic compositions and articles.
- In embodiments, the disclosure provides a group of glass-ceramic compositions each having lithium disilicate as a first major crystal phase, and at least one of wollastonite, fluoroapatite, cristobalite, β-quartz, lithiophosphate, or a mixture thereof, as a second minor phase.
- In embodiments, the disclosed compositions can comprise a source of, for example, 50 to 75 wt % SiO2, 1 to 5 wt % Al2O3, 1 to 8 wt % P2O5, 2 to 10 wt % CaO, 5 to 20 wt % Li2O, 0.5 to 5 wt % Na2O, 0.5 to 8 wt % ZrO2, and 0.1 to 1.0 F− wt % (i.e., fluoride ion), based on a 100 wt % total of the composition.
- In embodiments, the disclosed compositions can further comprise a source of, for example, 0.1 to 10 wt % B2O3, based on a 100 wt % total of the composition.
- In embodiments, the disclosure provides a glass-ceramic composition or glass-ceramic articles made from the composition, having a combination of high strength and high toughness.
- In embodiments, the disclosure provides a glass-ceramic composition having excellent biocompatibility.
- In embodiments, the disclosure provides methods of making and using the disclosed compositions.
- In embodiments of the disclosure:
-
FIG. 1 shows X-ray diffraction spectra ofexample compositions 7 to 10. All specimens were cerammed using a cycle of 700° C. for 2 hr and then 800° C. for 4 hr. -
FIGS. 2A to 2D show SEM images of polished surfaces inexample compositions 7 to 10 corresponding toFIGS. 2A, 2B, 2C, and 2D , respectively. -
FIGS. 3A to 3D show confocal SEM images of MC3T3 cell growth in disclosedcompositions 7 to 10 corresponding toFIGS. 3A, 3B, 3C, and 3D , respectively. -
FIGS. 4A and 4B showDay 1 attachment and proliferation of MC3T3 cells on disclosed bioactive glass-ceramic discs: absolute level (absolute cell number; 4A) and relative levels with respect to an in vitro control: a Tissue Culture Treated® (TCT) well (relative cell number; 4B). -
FIGS. 5A and 5B show cell proliferation results for disclosedcompositions 7 to 10. - Various embodiments of the disclosure will be described in detail with reference to drawings, if any. Reference to various embodiments does not limit the scope of the invention, which is limited only by the scope of the claims attached hereto. Additionally, any examples set forth in this specification are not limiting and merely set forth some of the many possible embodiments of the claimed invention.
- In embodiments, the disclosed method of making and using provide one or more advantageous features or aspects, including for example as discussed below. Features or aspects recited in any of the claims are generally applicable to all facets of the invention. Any recited single or multiple feature or aspect in any one claim can be combined or permuted with any other recited feature or aspect in any other claim or claims.
- “Glass,” “glasses,” or like terms can refer to a glass or a glass-ceramic.
- “Glass article,” or like terms can refer to any object made wholly or partly of any of the disclosed glass or glass-ceramic compositions.
- “Bioactivity Index” “index of bioactivity,” “IB,” or like terms or symbols refer to, for example, the time for more than 50% of the interface of a specific bioactive material to be bonded by a biological material such as bone, tissue, and like materials. Mathematically, a bioactivity index (according to Hench; see Cao, W., et al., Bioactive Materials, Ceramics International, 22 (1996) 493-507) is, IB=100/t0.5bb, where t0.5bb is the time for more than 50% of a bioactive material's interface, such as an implant, to be bonded by a biological material such as bone, tissue, and like materials, including osteoproductive (Class A having both intracellular and extracellular responses, e.g., 45S5 Bioglass®) and osteoconductive (Class B extracellular response only at interface, e.g., synthetic hydroxyapatite) materials.
- “Include,” “includes,” or like terms means encompassing but not limited to, that is, inclusive and not exclusive.
- “About” modifying, for example, the quantity of an ingredient in a composition, concentrations, volumes, process temperature, process time, yields, flow rates, pressures, viscosities, and like values, and ranges thereof, or a dimension of a component, and like values, and ranges thereof, employed in describing the embodiments of the disclosure, refers to variation in the numerical quantity that can occur, for example: through typical measuring and handling procedures used for preparing materials, compositions, composites, concentrates, component parts, articles of manufacture, or use formulations; through inadvertent error in these procedures; through differences in the manufacture, source, or purity of starting materials or ingredients used to carry out the methods; and like considerations. The term “about” also encompasses amounts that differ due to aging of a composition or formulation with a particular initial concentration or mixture, and amounts that differ due to mixing or processing a composition or formulation with a particular initial concentration or mixture.
- “Optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
- The indefinite article “a” or “an” and its corresponding definite article “the” as used herein means at least one, or one or more, unless specified otherwise.
- Abbreviations, which are well known to one of ordinary skill in the art, may be used (e.g., “h” or “hrs” for hour or hours, “g” or “gm” for gram(s), “mL” for milliliters, “rt” for room temperature, “nm” for nanometers, and like abbreviations).
- Specific and preferred values disclosed for components, ingredients, additives, dimensions, conditions, times, and like aspects, and ranges thereof, are for illustration only; they do not exclude other defined values or other values within defined ranges. The composition and methods of the disclosure can include any value or any combination of the values, specific values, more specific values, and preferred values described herein, including explicit or implicit intermediate values and ranges.
- Bioactive materials having high strength and toughness are in significant demand, for example, for the regeneration of bone and teeth. Glass-ceramics based on lithium disilicate offer highly desirable mechanical properties, including high body strength and fracture toughness, due to their microstructures of randomly-oriented interlocking crystals. Glass-ceramics having fracture toughness values of 2 to 3 MPa·m1/2 are achievable in the system of glass-ceramics based on lithium disilicate compositions (see commonly owned and assigned U.S. Ser. No. 61/874,870). Lithium disilicate glass-ceramics have been widely used in the fabrication of single and multiple dental restorations. However, these glass-ceramics have not been used in bone repair due to their relatively low bioactivity. In contrast, bioceramics based on apatite and wollastonite have demonstrated high bioactivity but do not have sufficient mechanical strength compared to, for example, cortical bone (Hench, L. L., Bioceramics, J Am Ceram Soc, 1998, 81: 1705-1728).
- In embodiments, the disclosure provides a group of glass-ceramic compositions having a phase assemblage containing a major phase of lithium disilicate and a minor phase or phases of, for example, apatite or wollastonite. These superior compositions exhibit an excellent combination of high mechanical strength and high bioactivity, which makes them excellent for hard tissue regeneration.
- WO 2015200017 ('017), entitled “Process for producing a sintered lithium disilicate glass ceramic dental restoration and kit of parts,” mentions a process for producing a sintered lithium disilicate glass ceramic dental restoration out of a porous 3-dim article. In contrast, the presently disclosed compositions have a different phase assemblage, for example, the disclosed compositions have lithium disilicate and apatite, whereas '017 has only lithium disilicate, and the presently disclosed compositions are bioactive but not the '017 compositions. Additionally, the presently disclosed compositions have CaO and F− to produce the apatite phase.
- US 20150087493 mentions lithium disilicate apatite glass-ceramics, which are characterized by a high chemical stability and can be used as restoration material in dentistry. However, these materials all include K2O, which is absent from the presently disclosed compositions.
- U.S. Pat. No. 7,166,548 mentions an apatite glass ceramic, which contains at least one glass phase and at least one apatite phase and is characterized in that at least one of the apatite phases is a phosphate-free and fluorine-free siliceous oxyapatite phase. However, these materials exclude phosphate and fluorine, which is present in the presently disclosed compositions.
- In embodiments, the disclosure provides a glass-ceramic composition, comprising:
-
- a first crystalline phase comprised of lithium disilicate; and
- a second crystalline phase selected from the group consisting of at least one of: wollastonite, fluoroapatite, cristobalite, β-quartz, lithiophosphate, or a combination thereof.
- In embodiments, the disclosure provides a glass-ceramic composition wherein the first crystalline phase and the second crystalline phase, in combination, comprise a source of:
-
- 50 to 75 wt % SiO2,
- 1 to 5 wt % Al2O3,
- 1 to 8 wt % P2O5,
- 2 to 10 wt % CaO,
- 5 to 20 wt % Li2O,
- 0.5 to 5 wt % Na2O,
- 0.5 to 8 wt % ZrO2, and
- 0.1 to 1.0 wt % F−, i.e., fluoride ion, based on a 100 wt % total of the composition.
- In embodiments, the glass-ceramic composition can further comprise a source of 0.1 to 10 wt % B2O3, based on a 100 wt % total of the composition.
- In embodiments, the first crystalline phase and the second crystalline phase, in combination, can comprise a source of:
-
- 50 to 60 wt % SiO2,
- 1 to 3 wt % Al2O3,
- 2 to 6 wt % P2O5,
- 4 to 8 wt % CaO,
- 7.5 to 12.5 wt % Li2O,
- 0.5 to 2 wt % Na2O,
- 1 to 4 wt % ZrO2, and
- 0.2 to 0.8 wt % F−, based on a 100 wt % total of the composition.
- In embodiments, the abovementioned composition can be a preferred or a most preferred composition and can comprise, consist of, or consist essentially of, the abovementioned composition components.
- In embodiments, the disclosed bioactive compositions and articles can be a preferred or most preferred composition or article and can comprise, consist of, or consist essentially of, the disclosed bioactive composition or article.
- In embodiments, the disclosed methods of making and methods of using can be a preferred or most preferred method and can comprise, consist of, or consist essentially of, the disclosed methods.
- In embodiments, the composition can have a high strength of from 200 MPa to 500 MPa, for example, from at least 200 MPa, at least 300 MPa, or at least 400 MPa, including intermediate values and ranges.
- In embodiments, the composition can have a high fracture toughness of from 1.4 to 2.0 MPa·m1/2, for example, from at least 1.4, 1.6, 1.8, or 2.0 MPa·m1/2, including intermediate values and ranges.
- In embodiments, the composition can have a combination of high strength of from 200 MPa to 500 MPa, and high fracture toughness of from 1.4 to 2.0 MPa·m1/2.
- In embodiments, the composition can be prepared from a precursor glass composition comprising a source of, for example:
-
- 50 to 75 wt % SiO2,
- 1 to 5 wt % Al2O3,
- 1 to 8 wt % P2O5,
- 2 to 10 wt % CaO,
- 5 to 20 wt % Li2O,
- 0.5 to 5 wt % Na2O,
- 0.5 to 8 wt % ZrO2, and
- 0.1 to 1.0 wt % F−, based on a 100 wt % total of the composition.
- In embodiments, the abovementioned precursor glass composition does not change significantly upon ceramming.
- In embodiments, the disclosure provides a method of making the abovementioned glass-ceramic compositions comprising, for example:
-
- ceramming a precursor glass comprising a source of:
- 50 to 75 wt % SiO2,
- 1 to 5 wt % Al2O3,
- 1 to 8 wt % P2O5,
- 2 to 10 wt % CaO,
- 5 to 20 wt % Li2O,
- 0.5 to 5 wt % Na2O,
- 0.5 to 8 wt % ZrO2, and
- 0.1 to 1.0 wt % F−, based on a 100 wt % total of the composition, by heating the glass at 650 to 750° C. for 0.5 to 10 hrs, and then heating at 750 to 850° C. for 0.5 to 20 hrs.
- In embodiments, the method of making can further comprise, for example, ion exchanging the resulting glass-ceramic composition to create at least one compressive stress layer on at least one surface of the article to increase mechanical strength of the article.
- In embodiments, the disclosure provides a bioactive composition, comprising:
-
- a glass-ceramic comprised of:
- a first crystalline phase comprised of lithium disilicate; and
- a second crystalline phase selected from the group consisting of at least one of: wollastonite, fluoroapatite, cristobalite, β-quartz, lithiophosphate, or a combination thereof; and
- one or more live osteoblast cells, that is, a bioactive glass-ceramic including the disclosed composition and cells capable of synthesizing bone.
- a glass-ceramic comprised of:
- In embodiments, in the abovementioned bioactive composition the glass-ceramic composition can comprise, for example, a source of:
-
- 50 to 75 wt % SiO2,
- 1 to 5 wt % Al2O3,
- 1 to 8 wt % P2O5,
- 2 to 10 wt % CaO,
- 5 to 20 wt % Li2O,
- 0.5 to 5 wt % Na2O,
- 0.5 to 8 wt % ZrO2, and
- 0.1 to 1.0 wt % F−, based on a 100 wt % total of the composition.
- In embodiments, the glass-ceramic composition can comprise, for example, a source of:
-
- 50 to 60 wt % SiO2,
- 1 to 3 wt % Al2O3,
- 2 to 6 wt % P2O5,
- 4 to 8 wt % CaO,
- 7.5 to 12.5 wt % Li2O,
- 0.5 to 2 wt % Na2O,
- 1 to 4 wt % ZrO2, and
- 0.2 to 0.8 wt % F−, based on a 100 wt % total of the composition.
- In embodiments, the abovementioned bioactive composition can further comprise, for example, a source of 0.1 to 10 wt % B2O3, based on a 100 wt % total of the composition.
- In embodiments, the disclosure provides a method of culturing osteoblast cells, i.e., a method of using the disclosed bioactive composition, comprising, for example:
-
- contacting the abovementioned bioactive composition with a suitable liquid medium.
- In embodiments, the glass-ceramic composition of the bioactive composition can be combined or contacted with the suitable liquid medium prior to being contacted with the live osteoblast cell(s).
- In embodiments, the contacting produces a proliferation of the osteoblast cells on the surface of the bioactive composition.
- In embodiments, the contacting produces a proliferation of the osteoblast cells in the suitable liquid medium, such as the culture medium of MC3T3 cells: i.e., alpha-MEM supplemented with 10% fetal bovine serum and 1 mM sodium pyruvate.
- In embodiments, the suitable liquid medium can include, for example, a simulated body fluid (SBF) composition. SBF is used for testing apatite formation activity of bioactive glasses/glass-ceramics. The disclosed bioactive glass-ceramics form in-situ a biologically active apatite layer (e.g., the mineral phase of bone and teeth) that can bond to bone and teeth, and can even bond to soft tissue. The potential applications of the disclosedbioactive glass-ceramics can include, for example, monolithic articles, composites, films, coating, or like forms, for use in repair of load-bearing bones, dental regeneration, treatment of dental hypersensitivity, artificial vertebrae, spinous spacers, intervertebral spacers, iliac spacers, granular fillers, scaffolds, middle-ear implant and in other types of small-bone replacement, wound healing, and like applications. The disclosed bioactive glass-ceramics are biocompatible with, for example, osteoblasts, keratinocytes, human umbilical vein endothelial cells (HUVEC), etc. (see for example, T. Kokubo et al., “How useful is SBF in predicting in vivo bone bioactivity?”, Biomaterials, 27[15] 2907-15 (2006)).
- In embodiments, the disclosed compositions and disclosed bioactive compositions can also have application in, for example: angiogenesis (HUVEC cells), wound healing (keratinocytes), bone tissue engineering (MC3T3 cells), and like applications.
- In embodiments, the disclosed composition is biocompatible with various cell types in various applications, and are biologically active (i.e., bioactive).
- In embodiments, the disclosed compositions and methods thereof are advantaged in several aspects, including for example:
-
- glass-ceramic compositions having a combination of high strength and high toughness;
- glass-ceramic compositions having excellent biocompatibility; and
- glass-ceramic compositions having a capability of supporting the growth and functionalization of osteoblastic cells.
- In embodiments, the disclosed bioactive glass-ceramic compositions can further comprise, for example, a form factor selected from a hollow microsphere, a solid microsphere, or a combination thereof, that is, where the glass composition has a particle shape, such as a sphere, an elongated sphere or egg-shape, a rod, or like geometries. Table 1 lists representative examples of the disclosed compositions. The ceramming cycle for all examples 1 to 15 was 700° C. for 2 hr and 800° C. for 4 hr.
-
TABLE 1 Example compositions (Ex. 7 to 15) and control compositions (Ex. C-1 to C-6). Oxides (wt %) C-11 C-2 C-3 C-4 C-5 C-6 7 8 SiO2 70 65 60 55 60 60 70 65 B2O3 0 0 0 0 0 0 0 0 Al2O3 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 Li2O 12 12 12 12 15 12 12 12 Na2O 2 2 2 2 2 2 2 2 CaO 6 6 6 6 6 6 6 6 P2O5 4 4 4 4 4 4 4 4 ZrO2 2 2 2 2 2 4 2 2 F −0 0 0 0 0 0 0.5 0.5 Phase A A A B C D E E assemblage2 Flexural — — — — — — 504 407 strength (MPa) Fracture — — — — — — 1.8 1.9 toughness (MPa•m1/2) Oxides (wt %) 9 10 11 12 13 14 15 SiO2 60 55 60 60 60 60 60 B2O3 0 0 0 0 2 4 6 Al2O3 2.5 2.5 2.5 2.5 2.5 2.5 2.5 Li2O 12 12 15 12 12 12 12 Na2O 2 2 2 2 2 2 2 CaO 6 6 6 6 6 6 6 P2O5 4 4 4 4 4 4 4 ZrO2 2 2 2 4 2 2 2 F− 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Phase F G G H F F F assemblage2 Flexural 485 303 — — — — — strength (MPa) Fracture 2.2 2.2 — — — — — toughness (MPa•m1/2) 1. “C-#” designation represents a control example (i.e., C- to C-6). 2. Phase assemblage key: A = Lithium disilicate, cristobalite, wollastonite, β-quartz, lithiophosphate. B = Lithium disilicate, wollastonite, lithiophosphate. C = Lithium disilicate, lithium metasilicate, wollastonite, lithiophosphate. D = Lithium disilicate, β-quartz, lithiophosphate. E = Lithium disilicate, cristobalite, fluoroapatite, β-quartz. F = Lithium disilicate, fluoroapatite, β-quartz, lithiophosphate. G = Lithium disilicate, fluoroapatite, lithium metasilicate, β-quartz. H = Lithium disilicate, fluoroapatite, β-quartz. Sample Appearance: Samples of Examples 1 to 8 and 10 to 15 were translucent white; Example 9 was translucent/semi-transparent white. - In embodiments, the disclosed compositions can be free of (e.g., zero ppm or ppb), or substantially free of (e.g., trace amounts less than several ppm or ppb), at least one of, for example, K2O, K2CO3, Ca3(PO4)2, MgO, TiO2, As2O3, Sb2O3, or combinations or mixtures thereof.
- In embodiments, the disclosure provides precursor glass compositions that can be cerammed to produce glass-ceramics having excellent mechanical properties and biocompatibility. In embodiments, the disclosure provides glass-ceramics having high mechanical strength by forming an interlocking structure in the cerammed articles, which forces cracks to propagate along a tortuous path. Additionally, the presence of minor crystallite phases such as fluoroapatite and wollastonite in the disclosed compositions is beneficial to the growth, proliferation, and function of osteoblastic cell lines.
- In embodiments, the precursor glass or source glass can comprise, for example, 50 to 75 wt % SiO2, 1 to 5 wt % Al2O3, 5 to 20 wt % Li2O, 0.5 to 5 wt % Na2O, 0.5 to 8 wt % ZrO2, and 0.1 to 1.0 F− wt % (i.e., fluoride ion), based on a 100 wt % total of the composition. In embodiments, a more preferred precursor glass composition, can be, for example, 50 to 60 wt % SiO2, 1.0 to 3.0 wt % Al2O3, 0.1 to 4.0 wt % B2O3, 7.5 to 12.5 wt % Li2O, 0.5 to 2.0 wt % Na2O, 1.0 to 4.0 wt % ZrO2, and 0.2 to 0.8 wt % F ion based on a 100 weight percentage total (see Table 1).
- In embodiments, the precursor glasses can be cerammed into glass-ceramic articles having high crystallinity of, for example, 80% or more, such as 80 to 95%. The major crystallite phases are comprised of lithium disilicate. The minor crystallite phases can be comprised of, for example, fluoroapatite, wollastonite, cristobalite, β-quartz, lithiophosphate, or mixtures thereof depending on composition targeted.
- Referring to the Figures,
FIG. 1 shows X-ray diffraction spectra ofexample compositions 7 to 10, where thereference numerals example compositions 7 to 10, respectively, in Table 1. The significant peaks are identified (with marker shapes) as: lithium disilicate (asterisk), lithium metasilicate (triangle), fluoroapatite (dot), beta-quartz (square), and cristobalite (diamond). All specimens were cerammed using a cycle of 700° C. for 2 hr and then 800° C. for 4 hr. - In embodiments, the disclosed glass-ceramic articles composed of interlocking lithium disilicate can be easily obtained by ceramming precursor glasses at temperatures of from 700 to 900° C. for a period of time. A grain size of the lithium disilicate phase can be larger than 1 micrometer having a high aspect ratio that is typically formed in glass-ceramics.
FIGS. 2A to 2D show SEM images of polished surfaces inexample compositions 7 to 10 corresponding toFIGS. 2A, 2B, 2C, and 2D , respectively. All specimens were cerammed using a cycle of 700° C. for 2 hr and then 800° C. for 4 hr. Specimens were etched in 1% HF for one min prior to observation. - Although not bound by theory, it is believed that the presence of interlocking crystals can be a significant factor in developing toughening mechanisms including, for example, crack deflection and tortuous crack path, which mechanisms can contribute to the observed high fracture toughness and high flexural strength (Table 1). For example, a fracture toughness of over 1.5 MPa·m1/2 and a flexural strength of over 300 MPa can be achieved in selected glass-ceramic compositions.
- In embodiments, the disclosed glass-ceramic product or residual glass can be ion exchanged to create a compressive stress layer in the surface of a ware to further improve mechanical strength.
- In embodiments, excellent biocompatibility was demonstrated in the disclosed glass-ceramic compositions. Cell attachment was clearly observed through confocal images on the surfaces of
compositions 7 to 9. MC 3T3 cells were cultured one day, fixed with 4% formaldehyde, and then stained with Alexa Fluor 568 phalloidin and DAPI prior to the confocal imaging.FIGS. 3A to 3D show confocal SEM images of MC3T3 cell growth in the disclosedcompositions 7 to 10 corresponding toFIGS. 3A, 3B, 3C, and 3D , respectively. All specimens were cerammed using a cycle of 700° C. for 2 hr and then 800° C. for 4 hr. Cells were cultured one day, fixed with 4% formaldehyde, and then stained with Alexa Fluor 568 phalloidin and DAPI prior to the confocal imaging. - The ability of the disclosed glass-ceramics of
examples compositions 7 to 10 to support cell proliferation was demonstrated by the expression of DNA from the cultured cells for absolute levels (FIG. 5A ) and for relative levels (FIG. 5B ) with respect to a TCT control. MCT3 cells were cultured on glass-ceramic discs. On day 4 andday 7, cells were digested with the digestion buffer (125 microgm/mL papain, 2 mM L-cysteine, 2 mMM EDTA) at 65° C. for overnight, the dsDNA amount was measured using Quant-iT™ PicoGreen® dsDNA Kit (Thermo Fisher). The increase of DNA concentration with increasing culture time provided additional evidence of the excellent biocompatibility of the disclosed compositions. - In embodiments, the disclosed glass-ceramics can be manufactured using a thin rolling, a float, a casting process, and like methods; and scaffolds can be produced using, for example, rapid prototyping, polymer foam replication, particle sintering, and like methods. Glass-ceramics of desired forms can be used to support cell growth and hard tissue regeneration.
- In embodiments, the realized mechanical strength, biocompatibility, and biodegradation of the disclosed compositions can be influenced by the glass compositions. In embodiments, the disclosed glass compositions can further include, for example: SiO2 which serves as the primary glass-forming oxide for precursor glass and can function to stabilize the networking structure of glass and glass-ceramics. In embodiments, the concentration of SiO2 should be sufficiently high to form a lithium disilicate crystal phase when the precursor glass is heat treated to convert to a glass-ceramic (i.e., cerammed). However, the glasses can't contain too much SiO2 since the melting temperature (200 poise temperature) of pure SiO2 or high-SiO2 glasses is undesirably high. In embodiments, glass or glass-ceramic compositions can comprise, for example, 68 to 82 wt % SiO2, based on a 100 wt % total weight.
- In embodiments, the Al2O3 may also provide stabilization to the networking structure. Al2O3 is favorable to the improvement of mechanical properties and chemical durability. However, too much Al2O3 generally increases the viscosity of the melt and decreases the fraction of lithium disilicate crystals to an extent that no interlocking structure can be formed. The Al2O3 concentration is preferably maintained in a reasonable range of, for example, from 1 to 5 wt %.
- In embodiments, the addition of B2O3 can be beneficial to improved crack-resistance of the glass-ceramics, which is helpful for dental applications. Furthermore, a higher boron concentration can increase the degradation rate of the bioactive compositions, which property may be desired in applications such as bone regeneration.
- Li2O is another significant component in the disclosed precursor glass compositions. Li2O is advantageous for forming lithium disilicate crystal phases. Li2O is called for to have at least 8 wt % Li2O to obtain glass-ceramics having lithium disilicate as a predominant phase. However, when the Li2O content gets too high, such as greater than 15 wt %, the precursor glasses become very fluid with low resistivity making it difficult to melt or form.
- In embodiments, the disclosed glass and glass-ceramic compositions can include, for example, from 2 to 6 wt % P2O5, for example, as a nucleating agent to produce bulk nucleation. If the P2O5 concentration is too low, such as less than 2 wt %, the precursor glass does not crystallize. If the P2O5 concentration is too high, such as greater than 6 wt %, the devitrification upon cooling during precursor glass forming, can be difficult to control.
- In embodiments, divalent cation oxides, such as alkaline earth oxides, can also be used to improve the melting behavior and the bioactivity of the glass. For example, CaO was found to combine with P2O5 to form apatite, or with SiO2 to form wollastonite. Both apatite and wollastonite are known bioactive ceramics (see Hench, L. L., supra.).
- In embodiments, including Na2O in the precursor glass in an amount of from 0.1 to 5 wt % can reduce the melting temperature of the precursor glass, and can shorten the ceramming cycle. Furthermore, including Na2O in the precursor glass can also increase the thermal expansion after ceramming if a higher thermal expansion (i.e., CTE) is desired in the glass-ceramic articles.
- In embodiments, melting was accomplished at an elevated temperature, such as above 1300° C., to fuse the precursor glass materials. In embodiments, ceramming was the heat treatment of the melted glass that was used to crystallize the glass into a glass-ceramic material.
- The following Examples demonstrate making, use, and analysis of the disclosed compositions and methods in accordance with the above general procedures.
- Preparation of Control Examples C-1 to C-6 and Actual Example Glass-
Ceramic Compositions 7 to 15 - Control and Actual Example Glass-
Ceramic Compositions 1 to 15 listed in Table 1, and their respective glass source materials in the indicated amounts, including for example, silica, boric acid, alumina, lithium carbonate, sodium carbonate, limestone, spodumene, aluminum metaphosphate, were individually combined and melted in an electric furnace. Prior to melting, the precursor glass source materials were vigorously mixed in a plastic jar using a Turbula® mixer. Then the mixtures were transferred to a platinum crucible with an internal volume of approximately 650 cc and heated at 700° C. for 2 hr then 800° C. for 4 hr, and then the glass melt was poured on a steel plate, and annealed at 500° C. - Preparation of Glass-Ceramic Discs
- Glass-ceramic discs were prepared from cerammed parts. Precursor glass patties were cerammed in an electronic furnace using a cycle of 700° C. to 2 hr for nucleation and then 800° C. for 4 hr for crystal growth. After ceramming, the discs (12.5 mm in diameter×2.0 mm thick) were core-drilled using a diamond drill, and then ground and polished to a 1.0 micrometer finish using a CeO2 slurry. All finished discs were cleaned by sonicating in an ultrasonic sonicator for 10 min.
- Glass-ceramic discs of Example 2 (made from compositions of the above working Example 1) were placed in wells of 24 well tissue culture treated microplates. Each composition has duplicate discs. MC 3T3 cells were then seeded (20K/2 mL) into the wells and some wells without any discs (Tissue Culture Treated (TCT) control). The microplates were cultured for 1, 4, or 7 days. Cells in the 1 day culture microplate were fixed with 4% formaldehyde, and then stained with Alexa Fluor 568 phalloidin and DAPI prior to the confocal imaging.
-
FIGS. 4A and 4B show Day 1 attachment and proliferation of MC3T3 cells on disclosed bioactive glass-ceramic discs ofExample compositions -
FIGS. 5A and 5B show cell proliferation results for disclosedcompositions 7 to 10. Cells in the day 4 (D4) and day 7 (D7) culture plates were digested with the digestion buffer (125 microg/mL papain, 2 mM L-cysteine, 2 mM EDTA) at 65° C. for 16 hrs, the dsDNA amount was measured using Quant-iT™ PicoGreen® dsDNA Kit (Thermo Fisher). The increase of DNA concentration with increasing culture time provides additional evidence of their excellent biocompatibility. - MC3T3 cells were digested with papain and the amount of DNA was measured using a PicoGreen assay. D4 or D7 refers to Day 4 or Day 7 (as in “the 4th day or 7th day of cell culture”). TCT refers to a tissue culture treated microplate substrate available from Corning, Inc®. Glass-ceramic discs were placed in wells of 24 well tissue culture treated microplates. Each composition has duplicate discs. MC 3T3 cells were then seeded (20K/2 mL) into the wells and some wells without any discs (TCT control). The microplates were cultured for 4 or 7 days. On the day 4 and
day 7, cells were digested with a digestion buffer (D-PBS containing 125 microg/mL papain, 2 mM L-cysteine, 2 mMM EDTA) at 65° C. in humid environment with shaking (60 rpm) for 16 hrs. An attempt was made to remove the lysed DNA from glass-ceramic discs by pipetting digestion solution up and down on the discs. The collected digestion solution was briefly centrifuged to remove any remaining particles. The dsDNA amount in the supernatant was measured using Quant-iT™ PicoGreen® dsDNA Kit (Thermo Fisher) according to the manufacturer's instruction. - MC3T3E1 Subclone 14 (ATCC® CRL2594™)(see atcc.org/products/all/CRL-2594.aspx).
- Quant-iT™ PicoGreen® dsDNA Kit (Invitrogen, #P11496). This kit contains Quant-iT™ PicoGreen® dsDNA Reagent (10 vials, each containing 100 microL aliquots), 25 mL of 20×TE buffer, 1 mL of 100 microg/mL Lambda DNA (dsDNA standard), Papain (Sigma-Aldrich, #P4762-25MG), L-cysteine (Sigma-Aldrich, #C1276-10G), EDTA (Sigma-Aldrich, #E6511), D-PBS (Thermo Fisher, #14190), a shaker set to 65° C., and a plate reader.
- The disclosure has been described with reference to various specific embodiments and techniques. However, it should be understood that many variations and modifications are possible while remaining within the scope of the disclosure.
Claims (20)
1. A glass-ceramic composition, comprising:
a first crystalline phase comprised of lithium disilicate; and
a second crystalline phase selected from the group consisting of at least one of: wollastonite, fluoroapatite, cristobalite, β-quartz, lithiophosphate, or a combination thereof.
2. The glass-ceramic composition of claim 1 wherein the first crystalline phase and the second crystalline phase, in combination, comprise a source of:
50 to 75 wt % SiO2,
1 to 5 wt % Al2O3,
1 to 8 wt % P2O5,
2 to 10 wt % CaO,
5 to 20 wt % Li2O,
0.5 to 5 wt % Na2O,
0.5 to 8 wt % ZrO2, and
0.1 to 1.0 wt % F−, based on a 100 wt % total of the composition.
3. The glass-ceramic composition of claim 1 further comprising a source of 0.1 to 10 wt % B2O3, based on a 100 wt % total of the composition.
4. The glass-ceramic composition of claim 1 wherein the first crystalline phase and the second crystalline phase, in combination, comprise a source of:
50 to 60 wt % SiO2,
1 to 3 wt % Al2O3,
2 to 6 wt % P2O5,
4 to 8 wt % CaO,
7.5 to 12.5 wt % Li2O,
0.5 to 2 wt % Na2O,
1 to 4 wt % ZrO2, and
0.2 to 0.8 wt % F−, based on a 100 wt % total of the composition.
5. The glass-ceramic composition of claim 1 wherein the composition has a high strength of from 200 MPa to 500 MPa.
6. The glass-ceramic composition of claim 1 wherein the composition has a high fracture toughness of from 1.4 to 2.0 MPa·m1/2.
7. The glass-ceramic composition of claim 1 wherein the composition has a combination of high strength of from 200 MPa to 500 MPa, and high fracture toughness of from 1.4 to 2.0 MPa·m1/2.
8. The glass-ceramic composition of claim 1 wherein the first crystalline phase comprises lithium disilicate and the second crystalline phase comprises apatite, wollastonite, or a mixture thereof.
9. A glass-ceramic precursor glass composition comprising a source of:
50 to 75 wt % SiO2,
1 to 5 wt % Al2O3,
1 to 8 wt % P2O5,
2 to 10 wt % CaO,
5 to 20 wt % Li2O,
0.5 to 5 wt % Na2O,
0.5 to 8 wt % ZrO2, and
0.1 to 1.0 wt % F−, based on a 100 wt % total of the composition.
10. A method of making the glass-ceramic composition of claim 1 comprising:
ceramming a precursor glass mixture comprising a source of:
50 to 75 wt % SiO2,
1 to 5 wt % Al2O3,
1 to 8 wt % P2O5,
2 to 10 wt % CaO,
5 to 20 wt % Li2O,
0.5 to 5 wt % Na2O,
0.5 to 8 wt % ZrO2, and
0.1 to 1.0 wt % F−, based on a 100 wt % total of the composition, by heating the mixture at 650 to 750° C. for 0.5 to 10 hrs and then heating at 750 to 850° C. for 0.5 to 20 hrs.
11. The method of claim 10 further comprising ion exchanging the resulting glass-ceramic composition to create at least one compressive stress layer on at least one surface of the article to increase mechanical strength.
12. A bioactive composition, comprising:
a glass-ceramic comprised of:
a first crystalline phase comprised of lithium disilicate; and
a second crystalline phase selected from the group consisting of at least one of: wollastonite, fluoroapatite, cristobalite, β-quartz, lithiophosphate, or a combination thereof; and
at least one live osteoblast cell.
13. The bioactive composition of claim 12 wherein the glass-ceramic composition comprises a source of:
50 to 75 wt % SiO2,
1 to 5 wt % Al2O3,
1 to 8 wt % P2O5,
2 to 10 wt % CaO,
5 to 20 wt % Li2O,
0.5 to 5 wt % Na2O,
0.5 to 8 wt % ZrO2, and
0.1 to 1.0 wt % F−, based on a 100 wt % total of the composition.
14. The bioactive composition of claim 12 wherein the glass-ceramic composition comprises a source of:
50 to 60 wt % SiO2,
1 to 3 wt % Al2O3,
2 to 6 wt % P2O5,
4 to 8 wt % CaO,
7.5 to 12.5 wt % Li2O,
0.5 to 2 wt % Na2O,
1 to 4 wt % ZrO2, and
0.2 to 0.8 wt % F−, based on a 100 wt % total of the composition.
15. The bioactive composition of claim 14 further comprising a source of 0.1 to 10 wt % B2O3, based on a 100 wt % total of the composition.
16. A method of culturing osteoblast cells comprising:
contacting the bioactive composition of claim 12 with a suitable liquid medium.
17. The method of claim 16 wherein the contacting produces a proliferation of the osteoblast cells on the surface of the bioactive composition.
18. The method of claim 16 wherein the contacting produces a proliferation of the osteoblast cells in the suitable liquid medium.
19. The method of claim 18 wherein the suitable liquid medium includes a simulated body fluid composition.
20. An article comprising the glass-ceramic composition of claim 1 .
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/603,006 US20170342383A1 (en) | 2016-05-27 | 2017-05-23 | Lithium disilicate glass-ceramic compositions and methods thereof |
US16/163,013 US11814649B2 (en) | 2016-05-27 | 2018-10-17 | Lithium disilicate glass-ceramic compositions and methods thereof |
US18/376,260 US20240026296A1 (en) | 2016-05-27 | 2023-10-03 | Lithium disilicate glass-ceramic compositions and methods thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662342381P | 2016-05-27 | 2016-05-27 | |
US15/603,006 US20170342383A1 (en) | 2016-05-27 | 2017-05-23 | Lithium disilicate glass-ceramic compositions and methods thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/163,013 Division US11814649B2 (en) | 2016-05-27 | 2018-10-17 | Lithium disilicate glass-ceramic compositions and methods thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170342383A1 true US20170342383A1 (en) | 2017-11-30 |
Family
ID=59014807
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/603,006 Abandoned US20170342383A1 (en) | 2016-05-27 | 2017-05-23 | Lithium disilicate glass-ceramic compositions and methods thereof |
US16/163,013 Active 2039-01-11 US11814649B2 (en) | 2016-05-27 | 2018-10-17 | Lithium disilicate glass-ceramic compositions and methods thereof |
US18/376,260 Pending US20240026296A1 (en) | 2016-05-27 | 2023-10-03 | Lithium disilicate glass-ceramic compositions and methods thereof |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/163,013 Active 2039-01-11 US11814649B2 (en) | 2016-05-27 | 2018-10-17 | Lithium disilicate glass-ceramic compositions and methods thereof |
US18/376,260 Pending US20240026296A1 (en) | 2016-05-27 | 2023-10-03 | Lithium disilicate glass-ceramic compositions and methods thereof |
Country Status (6)
Country | Link |
---|---|
US (3) | US20170342383A1 (en) |
EP (2) | EP3950617A1 (en) |
JP (2) | JP7221696B2 (en) |
KR (3) | KR102420123B1 (en) |
CN (1) | CN109311731A (en) |
WO (1) | WO2017205596A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10059621B2 (en) | 2016-05-27 | 2018-08-28 | Corning Incorporated | Magnetizable glass ceramic composition and methods thereof |
DE102018104839A1 (en) * | 2018-03-02 | 2019-09-05 | Friedmar Hütter | ear implant |
US10647962B2 (en) | 2016-05-27 | 2020-05-12 | Corning Incorporated | Bioactive aluminoborate glasses |
US10676713B2 (en) | 2016-05-27 | 2020-06-09 | Corning Incorporated | Bioactive borophosphate glasses |
US10751367B2 (en) | 2016-05-27 | 2020-08-25 | Corning Incorporated | Bioactive glass microspheres |
US10857259B2 (en) | 2017-11-28 | 2020-12-08 | Corning Incorporated | Chemically strengthened bioactive glass-ceramics |
US10865140B2 (en) * | 2014-12-11 | 2020-12-15 | Corning Incorporated | X-ray induced coloration in glass or glass-ceramic articles |
US11198638B2 (en) | 2017-11-28 | 2021-12-14 | Corning Incorporated | Bioactive borate glass and methods thereof |
WO2022003186A1 (en) * | 2020-07-03 | 2022-01-06 | King's College London | Dental material |
US11274059B2 (en) | 2017-11-28 | 2022-03-15 | Corning Incorporated | Bioactive glass compositions and dentin hypersensitivity remediation |
CN114276021A (en) * | 2020-09-28 | 2022-04-05 | 株式会社哈斯 | Dental block for cutting and method for manufacturing same |
US11306021B2 (en) | 2018-11-26 | 2022-04-19 | Owens Coming Intellectual Capital, LLC | High performance fiberglass composition with improved elastic modulus |
US11384009B2 (en) | 2017-11-28 | 2022-07-12 | Corning Incorporated | High liquidus viscosity bioactive glass |
US11524918B2 (en) | 2018-11-26 | 2022-12-13 | Owens Corning Intellectual Capital, Llc | High performance fiberglass composition with improved specific modulus |
US11814649B2 (en) | 2016-05-27 | 2023-11-14 | Corning Incorporated | Lithium disilicate glass-ceramic compositions and methods thereof |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11680009B2 (en) * | 2017-12-01 | 2023-06-20 | Cdgm Glass Co., Ltd | Glass-ceramic and substrate thereof |
US20220089473A1 (en) * | 2019-01-16 | 2022-03-24 | Corning Incorporated | Glass-ceramics based on lithium disilicate, zircon, and apatite |
CN114349351A (en) * | 2019-03-06 | 2022-04-15 | 株式会社小原 | Inorganic composition product and crystallized glass |
EP4049981A1 (en) * | 2021-02-24 | 2022-08-31 | Ivoclar Vivadent AG | Glass ceramic with quartz mixed crystal phase |
US20220402809A1 (en) * | 2021-06-18 | 2022-12-22 | Corning Incorporated | Precursor glasses and transparent glass-ceramic articles formed therefrom and having improved mechanical durability |
CN116477843A (en) * | 2022-01-17 | 2023-07-25 | 荣耀终端有限公司 | Glass ceramic, reinforced glass, preparation method of glass ceramic, shell of electronic equipment, display screen of electronic equipment and electronic equipment |
JP2024045871A (en) * | 2022-09-22 | 2024-04-03 | 株式会社オハラ | crystallized glass |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2926665A (en) * | 1957-12-12 | 1960-03-01 | Geraldine E Seese | Bandaging garment |
US20120135848A1 (en) * | 2010-11-30 | 2012-05-31 | George Halsey Beall | Fusion formed and ion exchanged glass-ceramics |
Family Cites Families (168)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2532386A (en) | 1949-09-27 | 1950-12-05 | Corning Glass Works | Colored phosphate glass |
NL232500A (en) | 1957-10-22 | |||
US2987339A (en) | 1960-01-27 | 1961-06-06 | Cullen Friestedt Company | Articulated lifter |
BE618737A (en) | 1961-06-12 | |||
US3323888A (en) | 1964-03-17 | 1967-06-06 | Cataphote Corp | Method for manufacturing glass beads |
US3778335A (en) | 1971-09-02 | 1973-12-11 | Corning Glass Works | Sodium aluminosilicate glass article strengthened by a surface compressive stress layer |
US4126437A (en) | 1976-12-02 | 1978-11-21 | Xerox Corporation | Magnetic glass carrier materials |
US4084972A (en) | 1977-01-07 | 1978-04-18 | Corning Glass Works | Glass-ceramics with metallic iron surfaces |
US4083727A (en) | 1977-01-07 | 1978-04-11 | Corning Glass Works | Glass-ceramics with magnetic surface films |
US4140645A (en) | 1978-06-12 | 1979-02-20 | Corning Glass Works | Glasses and glass-ceramics suitable for induction heating |
GB2035290B (en) | 1978-11-24 | 1982-11-10 | Standard Telephones Cables Ltd | Glass compositions and cements incorporating such compositions |
US4233169A (en) | 1979-04-13 | 1980-11-11 | Corning Glass Works | Porous magnetic glass structure |
US4323056A (en) | 1980-05-19 | 1982-04-06 | Corning Glass Works | Radio frequency induced hyperthermia for tumor therapy |
US4391646A (en) | 1982-02-25 | 1983-07-05 | Minnesota Mining And Manufacturing Company | Glass bubbles of increased collapse strength |
JPS60210546A (en) | 1984-04-02 | 1985-10-23 | Ngk Spark Plug Co Ltd | Crystallized glass for crown |
GB8612387D0 (en) | 1986-05-21 | 1986-07-16 | Univ Sheffield | Glass ceramics |
KR920001501B1 (en) | 1987-09-01 | 1992-02-15 | 가부시기가이샤 히다찌세이사구쇼 | Black matrix color picture tube and the method of the same |
US4889707A (en) | 1988-01-29 | 1989-12-26 | The Curators Of The University Of Missouri | Composition and method for radiation synovectomy of arthritic joints |
US5217928A (en) | 1988-08-24 | 1993-06-08 | Potters Industries, Inc. | Hollow glass spheres |
US5196381A (en) | 1990-01-16 | 1993-03-23 | E. I. Du Pont De Nemours And Company | Metaphosphate glass composition |
IT1240938B (en) | 1990-02-08 | 1993-12-27 | S.E.I.P.I. Societa' Esportazione Importazione Prodotti Industriali | BIOACTIVE GLASS COMPOSITION FOR BONE IMPLANTS AND PRODUCTS OBTAINED WITH SUCH A COMPOSITION OR THAT INCLUDE IT |
US5153070A (en) | 1990-08-01 | 1992-10-06 | Corning Incorporated | Coated refractory article and method |
US5252523A (en) | 1991-10-09 | 1993-10-12 | Corning Incorporated | Bioabsorbable chlorophosphate glasses and bioabsorbable glass-polymer blends made therefrom |
US5876452A (en) | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
JP3310291B2 (en) * | 1992-08-13 | 2002-08-05 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | Bioactive substance template for in vitro synthesis of bone tissue |
CA2121572A1 (en) | 1992-08-20 | 1994-03-03 | Jean Luc Bernard | Method for producing mineral wool, and mineral wool produced thereby |
US5648124A (en) | 1993-07-09 | 1997-07-15 | Seradyn, Inc. | Process for preparing magnetically responsive microparticles |
US5849816A (en) | 1994-08-01 | 1998-12-15 | Leonard Pearlstein | Method of making high performance superabsorbent material |
DE4428851C2 (en) | 1994-08-04 | 2000-05-04 | Diagnostikforschung Inst | Nanoparticles containing iron, their production and application in diagnostics and therapy |
US6254981B1 (en) | 1995-11-02 | 2001-07-03 | Minnesota Mining & Manufacturing Company | Fused glassy particulates obtained by flame fusion |
PT944556E (en) | 1995-11-14 | 2002-02-28 | Corning Inc | OPALINE GLASSES NOT CRYSTALLINE, SEPARATED BY PHASES |
US5674790A (en) | 1995-12-15 | 1997-10-07 | Corning Incorporated | Strengthening glass by ion exchange |
DE69731184T2 (en) | 1996-01-29 | 2005-10-13 | University Of Maryland, Baltimore | BIOACTIVE GLASS COMPOSITIONS FOR USE FOR THE TREATMENT OF DENTAL STRUCTURES |
JP4180657B2 (en) | 1996-01-29 | 2008-11-12 | ユニバーシティ オブ メリーランド、バルティモア | Bioactive glass composition |
US5735942A (en) | 1996-02-07 | 1998-04-07 | Usbiomaterials Corporation | Compositions containing bioactive glass and their use in treating tooth hypersensitivity |
US5707715A (en) | 1996-08-29 | 1998-01-13 | L. Pierre deRochemont | Metal ceramic composites with improved interfacial properties and methods to make such composites |
US6323549B1 (en) | 1996-08-29 | 2001-11-27 | L. Pierre deRochemont | Ceramic composite wiring structures for semiconductor devices and method of manufacture |
US5834008A (en) | 1996-09-19 | 1998-11-10 | U.S. Biomaterials Corp. | Composition and method for acceleration of wound and burn healing |
US6756060B1 (en) | 1996-09-19 | 2004-06-29 | Usbiomaterials Corp. | Anti-inflammatory and antimicrobial uses for bioactive glass compositions |
EP0930874A2 (en) | 1996-10-09 | 1999-07-28 | Takeda Chemical Industries, Ltd. | A method for producing a microparticle |
WO1998047830A1 (en) | 1997-04-18 | 1998-10-29 | Minnesota Mining And Manufacturing Company | Transparent beads and their production method |
DE19725555A1 (en) * | 1997-06-12 | 1998-12-24 | Ivoclar Ag | Translucent apatite glass-ceramic |
US6280863B1 (en) * | 1997-06-12 | 2001-08-28 | Ivoclar Ag | Translucent apatite glass ceramic |
US6034014A (en) | 1997-08-04 | 2000-03-07 | Owens Corning Fiberglas Technology, Inc. | Glass fiber composition |
GB9811661D0 (en) | 1998-06-01 | 1998-07-29 | Giltech Ltd | Compositions |
US6802894B2 (en) | 1998-12-11 | 2004-10-12 | Jeneric/Pentron Incorporated | Lithium disilicate glass-ceramics |
CA2343223C (en) | 1998-09-10 | 2014-08-12 | Usbiomaterials Corporation | Anti-inflammatory and antimicrobial uses for bioactive glass compositions |
US6214471B1 (en) | 1998-11-03 | 2001-04-10 | Corning Incorporated | Glasses compatible with aluminum |
JP2001010843A (en) | 1999-04-30 | 2001-01-16 | Ohara Inc | Crystalline low-melting glass and sealing composition |
IT1313655B1 (en) | 1999-09-30 | 2002-09-09 | Techint Spa | GLASS FIBER COMPOSITION. |
US6328990B1 (en) | 1999-11-12 | 2001-12-11 | The Trustees Of The University Of Pennsylvania | Bioactive, degradable composite for tissue engineering |
JP2001247333A (en) | 1999-12-28 | 2001-09-11 | Ishizuka Glass Co Ltd | Glass composition for imparting antimicrobial properties, antimicrobial fiber, antimicrobial spun yarn and antimicrobial fabric |
US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
JP4323707B2 (en) | 2000-10-25 | 2009-09-02 | 富士通マイクロエレクトロニクス株式会社 | Flash memory defect management method |
US20040166172A1 (en) | 2001-03-27 | 2004-08-26 | Coni Rosati | Bioctive tissue abrasives |
US7597900B2 (en) | 2001-03-27 | 2009-10-06 | Schott Ag | Tissue abrasives |
US7166549B2 (en) | 2001-08-22 | 2007-01-23 | Schott Ag | Antimicrobial, anti-inflammatory, wound-healing and disinfecting glass and use thereof |
DE10141117A1 (en) | 2001-08-22 | 2003-03-13 | Schott Glas | Antimicrobial silicate glass and its use |
ATE332879T1 (en) | 2001-08-22 | 2006-08-15 | Schott Ag | ANTIMICROBIAL, ANTI-INFLAMMATORY, WOUND-HEALING GLASS POWDER AND USE THEREOF |
US20050085369A1 (en) | 2001-12-12 | 2005-04-21 | Jensen Soren L. | Fibres and their production |
US20050142077A1 (en) | 2001-12-12 | 2005-06-30 | Jose Zimmer | Usa of an antimicrobial glass ceramic for dental care and oral hygiene |
DE10203629A1 (en) | 2002-01-30 | 2003-07-31 | Ulrich Zimmermann | Device and method for producing microcapsules and improved microcapsule |
JP2003249763A (en) | 2002-02-25 | 2003-09-05 | Fujitsu Ltd | Multilayer interconnection board and manufacturing method thereof |
DE10214273A1 (en) | 2002-03-28 | 2003-10-23 | Schott Glas | Use of glass and/or glass ceramic powder and/or fiber for time- and quantity-controlled ion release is useful cosmetic or medicinal formulation as skin care cream and for healing or covering wound and treating chronic wound |
AU2003295538B9 (en) | 2002-11-15 | 2007-01-04 | Color Access, Inc. | Transparent concealing cosmetic compositions |
US20050118236A1 (en) | 2002-12-03 | 2005-06-02 | Gentis Inc. | Bioactive, resorbable scaffolds for tissue engineering |
EP1597211A2 (en) | 2003-02-25 | 2005-11-23 | Schott AG | Antimicrobial phosphate glass |
JP4293806B2 (en) | 2003-02-28 | 2009-07-08 | 石塚硝子株式会社 | Antibacterial imparting glass composition and antibacterial polymer composite material using the same |
CA2519030A1 (en) | 2003-03-24 | 2004-10-07 | Exa Sa | A treatment composition |
GB0310673D0 (en) | 2003-05-09 | 2003-06-11 | Givaudan Sa | Alginate matrix particles |
JP2004359754A (en) | 2003-06-03 | 2004-12-24 | Ishizuka Glass Co Ltd | Antimicrobial resin composition and its molding |
US8444756B2 (en) * | 2003-08-07 | 2013-05-21 | Ivoclar Vivadent Ag | Lithium silicate materials |
DE10336913C9 (en) | 2003-08-07 | 2019-02-21 | Ivoclar Vivadent Ag | Use of a lithium silicate material |
HU227595B1 (en) | 2003-08-07 | 2011-09-28 | Mta | Metal complexes of polygalacturonic acid and their production |
FR2867075B1 (en) | 2004-03-03 | 2006-07-14 | Ethypharm Sa | PROCESS FOR PREPARING CALIBRATED BIODEGRADABLE MICROSPHERES |
DE102004011520A1 (en) | 2004-03-08 | 2005-10-06 | Schott Ag | Antimicrobial refractive index adapted phosphate glass |
DE102004013455B3 (en) | 2004-03-18 | 2005-09-08 | Ivoclar Vivadent Ag | Apatite glass-ceramic useful for making dental materials comprises a glass phase and a phosphate- and fluorine-free silicate-based oxyapatite phase |
US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
DE102004026432A1 (en) | 2004-05-29 | 2005-12-22 | Schott Ag | Glass compositions as antimicrobial additive for dental materials and their use |
FR2873683B1 (en) | 2004-07-27 | 2007-06-15 | Inst Nat Sciences Appliq | POROUS BIOVERRE AND PROCESS FOR PREPARING THE SAME |
DE202004014053U1 (en) | 2004-09-07 | 2004-11-11 | Deep Colours! Gmbh | tattoo |
US20060127427A1 (en) | 2004-12-15 | 2006-06-15 | Vernice Joseph J | Surface coated abrasive material for cosmetic products |
DE102005001078A1 (en) | 2005-01-08 | 2006-07-20 | Schott Ag | Glass powder, in particular biologically active glass powder and process for the production of glass powder, in particular biologically active glass powder |
US9326995B2 (en) | 2005-04-04 | 2016-05-03 | The Regents Of The University Of California | Oxides for wound healing and body repair |
US7989065B2 (en) | 2005-05-20 | 2011-08-02 | Seradyn, Inc. | Magnetically-responsive microparticles with improved response times |
DE102005026269A1 (en) | 2005-06-08 | 2006-12-14 | Ivoclar Vivadent Ag | Dental glass-ceramics |
JP4226574B2 (en) | 2005-06-27 | 2009-02-18 | 株式会社ノリタケカンパニーリミテド | Glass composition having acid resistance |
JP2007039269A (en) | 2005-08-02 | 2007-02-15 | Asahi Glass Co Ltd | Glass for covering electrode, and plasma display device |
DE102005038070A1 (en) | 2005-08-10 | 2007-03-15 | Henkel Kgaa | Detergents and cleaners with well soluble capsules |
WO2007022264A2 (en) | 2005-08-15 | 2007-02-22 | The Regents Of The University Of California | Oxides for wound healing and body repair |
CN101454253B (en) | 2006-06-07 | 2011-05-11 | 兴亚硝子株式会社 | Mixed antibacterial glass |
GB0612028D0 (en) | 2006-06-16 | 2006-07-26 | Imp Innovations Ltd | Bioactive glass |
US20090324668A1 (en) | 2006-06-28 | 2009-12-31 | Ilkka Kangasniemi | Implant, its uses and methods for making it |
EP2032182A2 (en) | 2006-06-28 | 2009-03-11 | Vivoxid Oy | Implant containing a source of oxygen |
US9539062B2 (en) * | 2006-10-16 | 2017-01-10 | Natural Dental Implants, Ag | Methods of designing and manufacturing customized dental prosthesis for periodontal or osseointegration and related systems |
US8288344B2 (en) | 2007-03-15 | 2012-10-16 | Musculoskeletal Transplant Foundation | Ceramic composition for filling bone defects |
EP2030957A1 (en) | 2007-08-28 | 2009-03-04 | Corning Incorporated | Fugitive pore former for porous ceramic articles |
US9157054B2 (en) | 2007-11-14 | 2015-10-13 | The University Of Queensland | Device and method for preparing microparticles |
US20090258778A1 (en) | 2008-04-11 | 2009-10-15 | James R., Glidewell Dental Ceramics, Inc. | Lithium silicate glass ceramic for fabrication of dental appliances |
US9241879B2 (en) | 2008-04-11 | 2016-01-26 | James R. Glidewell Dental Ceramics, Inc. | Lithium silicate glass ceramic for fabrication of dental appliances |
CA2725253A1 (en) * | 2008-05-27 | 2009-12-03 | Imperial Innovations Limited | Process for producing porous scaffolds from sinterable glass |
CN101596326A (en) * | 2008-06-06 | 2009-12-09 | 华东理工大学 | A kind of borate biological microcrystalline glass and its production and application |
CN101407373B (en) | 2008-11-18 | 2011-12-28 | 湖北顶盛科技发展有限公司 | Strontium-reinforced bioactivity glass, production method there and use in tooth-cleaning products |
TWI391148B (en) | 2009-04-01 | 2013-04-01 | Colgate Palmolive Co | Non-aqueous dentifrice composition with bioacceptable and bioactive glass and methods of use and manufacture thereof |
EP2243749B1 (en) | 2009-04-23 | 2015-04-08 | PURAC Biochem BV | Resorbable and biocompatible fibre glass compositions and their uses |
CN101704632B (en) | 2009-11-30 | 2012-08-29 | 中国建材国际工程有限公司 | Preparation method of high-strength low-density hollow glass bead |
US20110152057A1 (en) | 2009-12-21 | 2011-06-23 | Gang Qi | Hollow microspheres |
US8173154B2 (en) | 2010-01-06 | 2012-05-08 | The Curators Of The University Of Missouri | Boron trioxide glass-based fibers and particles in dressings, sutures, surgical glue, and other wound care compositions |
EP2386525A1 (en) | 2010-05-13 | 2011-11-16 | Universitat Politècnica de Catalunya | Nanostructured material comprising a biocompatible calcium phosphate glass, sol-gel process for its preparation and medical use thereof |
US20160145567A1 (en) | 2010-05-27 | 2016-05-26 | Corning Incorporated | Cell culture article and methods thereof |
GB201010758D0 (en) | 2010-06-25 | 2010-08-11 | Queen Mary & Westfield College | Bioactive glass composition |
DE102010034083A1 (en) | 2010-08-12 | 2012-02-16 | Süd-Chemie AG | Magnetic glass particles for use in biogas plants, fermentation and separation processes |
CN101938877B (en) | 2010-09-19 | 2013-02-27 | 无锡力芯微电子股份有限公司 | LED driving circuit |
KR101262121B1 (en) * | 2010-12-27 | 2013-05-14 | 주식회사 하스 | Manufacturing method of high strength glass ceramics for teeth |
US20130266625A1 (en) | 2011-01-24 | 2013-10-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nanoparticles based on poly (lactic glycolic) acid for cosmetic applications |
PT105617A (en) * | 2011-04-05 | 2012-10-08 | Univ Aveiro | COMPOSITION OF BIOACTIVE GLASS, ITS USE AND RESPECTIVE METHOD OF OBTAINING |
WO2012177615A1 (en) | 2011-06-20 | 2012-12-27 | The Procter & Gamble Company | Liquid cleaning and/or cleansing composition |
US20120321567A1 (en) | 2011-06-20 | 2012-12-20 | Denis Alfred Gonzales | Liquid cleaning and/or cleansing composition |
GB201113754D0 (en) | 2011-08-09 | 2011-09-21 | Glaxo Group Ltd | Composition |
US20140000891A1 (en) | 2012-06-21 | 2014-01-02 | Self-Suspending Proppant Llc | Self-suspending proppants for hydraulic fracturing |
CA2851386C (en) | 2011-10-14 | 2017-07-11 | Ivoclar Vivadent Ag | Lithium silicate glass ceramic and glass with monovalent metal oxide |
PL2765974T3 (en) * | 2011-10-14 | 2016-08-31 | Ivoclar Vivadent Ag | Lithium silicate glass ceramic and lithium silicate glass comprising a divalent metal oxide |
CN102430149A (en) | 2011-11-18 | 2012-05-02 | 华东理工大学 | Phosphate glass fiber/chitosan composite material |
JP5859681B2 (en) * | 2012-01-20 | 2016-02-10 | ストラウマン ホールディング アーゲー | Prosthetic elements |
CN102526797B (en) | 2012-02-08 | 2013-10-30 | 同济大学 | Preparation method of high-strength biological glass bone bracket with regular-hole distribution |
KR20130112433A (en) | 2012-04-04 | 2013-10-14 | 주식회사 케이씨씨 | A composition for preparing glass wool and a biosoluble glass wool prepared therefrom |
KR20130112422A (en) | 2012-04-04 | 2013-10-14 | 이운덕 | Bike pedal cover for the protection of vehicle's rear |
EP2844213B1 (en) * | 2012-05-04 | 2019-12-04 | Ivoclar Vivadent AG | Lithium disilicate apatite glass ceramic |
ES2485381T3 (en) | 2012-05-30 | 2014-08-13 | Skulle Implants Oy | An implant |
US20150196585A1 (en) | 2012-07-19 | 2015-07-16 | Relypsa, Inc. | Compositions comprising crosslinked cation-binding polymers and uses thereof |
JP6008278B2 (en) | 2012-07-24 | 2016-10-19 | パナソニックIpマネジメント株式会社 | Lighting device, lighting apparatus using the same, and lighting system |
US20140026916A1 (en) | 2012-07-25 | 2014-01-30 | College Of William And Mary | Method for Reducing Marine Pollution Using Polyhydroxyalkanoate Microbeads |
ES2688381T3 (en) | 2012-09-28 | 2018-11-02 | Stelo Technologies | Methods for making silver nanoparticles and their applications |
WO2014095198A1 (en) | 2012-12-17 | 2014-06-26 | Unilever N.V. | Topical composition |
US20140212469A1 (en) | 2013-01-28 | 2014-07-31 | Missouri University Of Science And Technology | Surface functional bioactive glass scaffold for bone regeneration |
US20140219941A1 (en) | 2013-02-06 | 2014-08-07 | U.S. Cosmetic Corporation | Cosmetic powder coated with alginic acid and methods of making the same |
EP2969984A4 (en) | 2013-03-14 | 2017-01-11 | Novabone Products, LLC | Sodium containing sol-gel derived bioactive glasses and uses thereof including hemostasis |
WO2014159240A1 (en) | 2013-03-14 | 2014-10-02 | Novabone Products, Llc | Compositions and methods for manufacturing sol-gel derived bioactive borophosphate glasses for medical applicatons |
EP2792345B1 (en) * | 2013-04-15 | 2019-10-09 | Ivoclar Vivadent AG | Lithium silicate glass ceramic and glass with caesium oxide content |
CN103172263B (en) | 2013-04-16 | 2015-03-18 | 中国地质科学院 | Biological microcrystalline glass prepared by utilizing phosphate tailings and preparation method thereof |
US9359244B2 (en) | 2013-05-21 | 2016-06-07 | Colorado School Of Mines | Alumina-rich glasses and methods for making the same |
CN103449725B (en) | 2013-08-23 | 2016-03-30 | 四川大学 | A kind of biological activated glass ceramic material and preparation method thereof and the application in oral care implement |
US9701573B2 (en) * | 2013-09-06 | 2017-07-11 | Corning Incorporated | High strength glass-ceramics having lithium disilicate and beta-spodumene structures |
US10117668B2 (en) | 2013-10-08 | 2018-11-06 | The Spectranetics Corporation | Balloon catheter with non-deployable stent having improved stability |
KR101524482B1 (en) * | 2013-10-14 | 2015-06-02 | 주식회사 하스 | Glass-ceramics or Lithium silicate glass for Zirconia overlaying materials and preparation method thereof |
ES2891275T3 (en) * | 2013-11-05 | 2022-01-26 | Ivoclar Vivadent Ag | Lithium-apatite disilicate glass-ceramic with transition metal oxide |
JP2017505824A (en) | 2014-02-17 | 2017-02-23 | ザ プロクター アンド ギャンブル カンパニー | Skin cleansing composition comprising biodegradable abrasive particles |
US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
US9878940B2 (en) | 2014-02-21 | 2018-01-30 | Corning Incorporated | Low crystallinity glass-ceramics |
CN103979796B (en) | 2014-05-19 | 2016-08-24 | 白银金奇化工科技有限公司 | A kind of high intensity hollow glass micropearl and preparation method thereof |
EP3149985A1 (en) | 2014-06-02 | 2017-04-05 | Antique Books Inc. | Advanced proof of knowledge authentication |
US10507263B2 (en) | 2014-06-09 | 2019-12-17 | The Royal Institution For The Advancement Of Learning/Mcgill University | Borate-glass biomaterials |
EP3157461B1 (en) | 2014-06-23 | 2019-12-18 | 3M Innovative Properties Company | Process for producing a sintered lithium disilicate glass ceramic dental restoration |
CN104108883B (en) * | 2014-08-11 | 2019-03-08 | 中国地质大学(北京) | A kind of high intensity lithium bisilicate glass ceramics and preparation method thereof |
KR101648175B1 (en) * | 2014-08-29 | 2016-08-16 | 주식회사 하스 | Cristobalite crystal-containing lithium disilicate glass-ceramics with high strength and esthetics and preparation method thereof |
EP3805169A1 (en) * | 2014-10-08 | 2021-04-14 | Corning Incorporated | High strength glass-ceramics having petalite and lithium silicate structures |
US10201633B2 (en) | 2014-12-05 | 2019-02-12 | Augusta University Research Institute, Inc. | Glass composites for tissue augmentation, biomedical and cosmetic applications |
DE102015108171A1 (en) | 2015-05-22 | 2016-11-24 | Degudent Gmbh | Process for increasing the strength of shaped bodies consisting of lithium silicate glass-ceramic |
CN105236745A (en) | 2015-08-27 | 2016-01-13 | 陕西科技大学 | Ferromagnetic Fe3O4 nano micro-crystal glass and preparation method thereof |
CN105819697B (en) | 2016-03-29 | 2019-03-01 | 中材科技股份有限公司 | A kind of bio-compatible phosphate base continuous glass fibre and fabric prepared therefrom |
US10751367B2 (en) | 2016-05-27 | 2020-08-25 | Corning Incorporated | Bioactive glass microspheres |
US20170342383A1 (en) | 2016-05-27 | 2017-11-30 | Corning Incorporated | Lithium disilicate glass-ceramic compositions and methods thereof |
US10647962B2 (en) | 2016-05-27 | 2020-05-12 | Corning Incorporated | Bioactive aluminoborate glasses |
US20170340527A1 (en) | 2016-05-27 | 2017-11-30 | Corning Incorporated | Biodegradable microbeads |
US10676713B2 (en) | 2016-05-27 | 2020-06-09 | Corning Incorporated | Bioactive borophosphate glasses |
US10059621B2 (en) | 2016-05-27 | 2018-08-28 | Corning Incorporated | Magnetizable glass ceramic composition and methods thereof |
CN107028770B (en) | 2017-03-07 | 2020-04-17 | 中国人民解放军第四军医大学 | Dentin reactive monomer mixture and preparation method thereof, polycarboxy oligomer and preparation method thereof, and dental composite resin bonding system |
US10624994B2 (en) | 2017-08-30 | 2020-04-21 | King Abdulaziz University | Borate bioactive glass and methods of use for dentin and enamel restoration |
-
2017
- 2017-05-23 US US15/603,006 patent/US20170342383A1/en not_active Abandoned
- 2017-05-25 EP EP21198099.0A patent/EP3950617A1/en active Pending
- 2017-05-25 WO PCT/US2017/034421 patent/WO2017205596A1/en unknown
- 2017-05-25 KR KR1020187036262A patent/KR102420123B1/en active IP Right Grant
- 2017-05-25 KR KR1020227023280A patent/KR102571225B1/en active IP Right Grant
- 2017-05-25 KR KR1020237028370A patent/KR102650165B1/en active IP Right Grant
- 2017-05-25 JP JP2018561573A patent/JP7221696B2/en active Active
- 2017-05-25 EP EP17728385.0A patent/EP3464204B1/en active Active
- 2017-05-25 CN CN201780032893.XA patent/CN109311731A/en active Pending
-
2018
- 2018-10-17 US US16/163,013 patent/US11814649B2/en active Active
-
2022
- 2022-10-11 JP JP2022163061A patent/JP2023002619A/en active Pending
-
2023
- 2023-10-03 US US18/376,260 patent/US20240026296A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2926665A (en) * | 1957-12-12 | 1960-03-01 | Geraldine E Seese | Bandaging garment |
US20120135848A1 (en) * | 2010-11-30 | 2012-05-31 | George Halsey Beall | Fusion formed and ion exchanged glass-ceramics |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10865140B2 (en) * | 2014-12-11 | 2020-12-15 | Corning Incorporated | X-ray induced coloration in glass or glass-ceramic articles |
US11814649B2 (en) | 2016-05-27 | 2023-11-14 | Corning Incorporated | Lithium disilicate glass-ceramic compositions and methods thereof |
US10647962B2 (en) | 2016-05-27 | 2020-05-12 | Corning Incorporated | Bioactive aluminoborate glasses |
US10676713B2 (en) | 2016-05-27 | 2020-06-09 | Corning Incorporated | Bioactive borophosphate glasses |
US10751367B2 (en) | 2016-05-27 | 2020-08-25 | Corning Incorporated | Bioactive glass microspheres |
US10059621B2 (en) | 2016-05-27 | 2018-08-28 | Corning Incorporated | Magnetizable glass ceramic composition and methods thereof |
US11384009B2 (en) | 2017-11-28 | 2022-07-12 | Corning Incorporated | High liquidus viscosity bioactive glass |
US11198638B2 (en) | 2017-11-28 | 2021-12-14 | Corning Incorporated | Bioactive borate glass and methods thereof |
US11274059B2 (en) | 2017-11-28 | 2022-03-15 | Corning Incorporated | Bioactive glass compositions and dentin hypersensitivity remediation |
US10857259B2 (en) | 2017-11-28 | 2020-12-08 | Corning Incorporated | Chemically strengthened bioactive glass-ceramics |
US11446410B2 (en) | 2017-11-28 | 2022-09-20 | Corning Incorporated | Chemically strengthened bioactive glass-ceramics |
DE102018104839A1 (en) * | 2018-03-02 | 2019-09-05 | Friedmar Hütter | ear implant |
US11306021B2 (en) | 2018-11-26 | 2022-04-19 | Owens Coming Intellectual Capital, LLC | High performance fiberglass composition with improved elastic modulus |
US11524918B2 (en) | 2018-11-26 | 2022-12-13 | Owens Corning Intellectual Capital, Llc | High performance fiberglass composition with improved specific modulus |
WO2022003186A1 (en) * | 2020-07-03 | 2022-01-06 | King's College London | Dental material |
CN114276021A (en) * | 2020-09-28 | 2022-04-05 | 株式会社哈斯 | Dental block for cutting and method for manufacturing same |
Also Published As
Publication number | Publication date |
---|---|
KR20230127368A (en) | 2023-08-31 |
EP3464204A1 (en) | 2019-04-10 |
JP7221696B2 (en) | 2023-02-14 |
US20190048318A1 (en) | 2019-02-14 |
KR20220101756A (en) | 2022-07-19 |
JP2023002619A (en) | 2023-01-10 |
CN109311731A (en) | 2019-02-05 |
EP3464204B1 (en) | 2021-12-15 |
JP2019517449A (en) | 2019-06-24 |
US11814649B2 (en) | 2023-11-14 |
KR20190003780A (en) | 2019-01-09 |
KR102650165B1 (en) | 2024-03-21 |
WO2017205596A1 (en) | 2017-11-30 |
KR102571225B1 (en) | 2023-08-25 |
KR102420123B1 (en) | 2022-07-12 |
EP3950617A1 (en) | 2022-02-09 |
US20240026296A1 (en) | 2024-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240026296A1 (en) | Lithium disilicate glass-ceramic compositions and methods thereof | |
US11446410B2 (en) | Chemically strengthened bioactive glass-ceramics | |
US10647962B2 (en) | Bioactive aluminoborate glasses | |
US20220089473A1 (en) | Glass-ceramics based on lithium disilicate, zircon, and apatite | |
Kansal et al. | Diopside (CaO· MgO· 2SiO 2)–fluorapatite (9CaO· 3P 2 O 5· CaF 2) glass-ceramics: potential materials for bone tissue engineering | |
JPH07232931A (en) | Glass-ceramic biomaterial and its preparation | |
US20220298058A1 (en) | High liquidus viscosity bioactive glass | |
WO2022005781A9 (en) | Glass-ceramic compositions and methods of making thereof | |
Mukhopadhyay | Bioactive glass-ceramics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CORNING INCORPORATED, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DENG, HUAYUN;FU, QIANG;MAURO, JOHN CHRISTOPHER;SIGNING DATES FROM 20170503 TO 20170510;REEL/FRAME:042481/0816 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |